scholarly journals Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) Leukemia Cooperative Groups

2012 ◽  
Vol 91 (6) ◽  
pp. 825-835 ◽  
Author(s):  
Marysia Hengeveld ◽  
Stefan Suciu ◽  
Matthias Karrasch ◽  
Giorgina Specchia ◽  
Jean-Pierre Marie ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Maintenance Therapy ◽  
Myeloid Leukaemia ◽  
Phase Iii ◽  
Cooperative Groups ◽  
Consolidation Therapy ◽  
European Organization ◽  
Phase Iii Study ◽  
Acute Myeloid

The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia

1987 ◽  
Vol 66 (1) ◽  
pp. 37-44 ◽  
Author(s):  
G. Tricot ◽  
M. A. Boogaerts ◽  
R. Vlietinck ◽  
M. P. Emonds ◽  
R. L. Verwilghen
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Remission Induction ◽  
Consolidation Therapy ◽  
Acute Myeloid

Post consolidation therapy for adult patients with acute myeloid leukaemia

1991 ◽  
Vol 79 (2) ◽  
pp. 162-169 ◽  
Author(s):  
M. R. Ranson ◽  
J. H. Scarffe ◽  
G. R. Morgenstern ◽  
J. Chang ◽  
H. Anderson ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Adult Patients ◽  
Consolidation Therapy ◽  
Acute Myeloid

Elacytarabine — A New Agent in the Treatment of Relapsed/Refractory Acute Myeloid Leukaemia

2012 ◽  
Vol 08 (02) ◽  
pp. 111
Author(s):  
Norbert Vey ◽  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Liver Toxicity ◽  
Remission Rate ◽  
Single Agent ◽  
Phase Iii ◽  
Esterification Reaction ◽  
Control Group ◽  
Nucleoside Transporter ◽  
Acute Myeloid

The prognosis for patients with relapsed acute myeloid leukaemia (AML) is poor, and effective treatments for this patient group remain a substantially unmet clinical need. Elacytarabine is a promising new cytotoxic nucleoside agent made by an esterification reaction between cytarabine and elaidic acid, currently in development for use in the treatment of relapsed/refractory AML. Unlike cytarabine, cellular uptake of elacytarabine is independent of human equilibrative nucleoside transporter-1 (hENT-1) and results in prolonged intracellular retention of the active nucleoside. In addition, elacytarabine inhibits DNA synthesis for twice the duration seen with cytarabine and exhibits a different intracellular distribution. A Phase I trial in patients with AML identified a recommended dose of 2,000 mg/m²/day for five days and showed limited non-haematological side effects, liver toxicity being dose-limiting. Elacytarabine can be safely combined with idarubicin. A recent Phase II trial demonstrated an improved complete remission rate and overall survival with elacytarabine as a single agent in patients with advanced AML, as compared with a historical control group treated with second salvage therapy. Following these encouraging results, the results of an ongoing Phase III clinical trial comparing elacytarabine with the investigator’s choice of standard of care are awaited with interest.

Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia

2009 ◽  
Vol 47 (3) ◽  
pp. 229-233 ◽  
Author(s):  
I. P. Palva ◽  
A. Almqvist ◽  
E. Elonen ◽  
A. Hänninen ◽  
J. Jouppila ◽  
...  
Keyword(s):  
Acute Myeloid Leukaemia ◽  
Maintenance Therapy ◽  
Myeloid Leukaemia ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document